Breast Cancer

Share

Program Content

Activities

  • ASCO to Clinic: Breast Cancer
    Conference to Clinic: Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 14, 2023

  • Conference to Clinic: Breast Cancer
    Conference to Clinic: Expert Analysis of the Top Breast Cancer Abstracts From the 2023 Oncology Meeting in Chicago
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 03, 2023

    Expires: July 02, 2024

  • ASCO 2023 Breast Cancer
    Key Studies in Breast Cancer: Independent Conference Coverage of the 2023 ASCO Annual Meeting
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 18, 2023

    Expires: August 17, 2024

Activities

monarchE Subgroup Analysis by Age
monarchE Subgroup Analysis by Age: Adjuvant Abemaciclib + ET in Older vs Younger Patients With High-Risk, Node-Positive HR+/HER2- EBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2023

Ovarian Ablation/Suppression in BC
EBCTCG Meta-analysis of Breast Cancer Recurrence and Survival Following Ovarian Ablation or Suppression in Premenopausal Women
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

SONIA
SONIA: Phase III Trial Assessing the Optimal Therapeutic Position of CDK4/6 Inhibitors for Patients With HR+/HER2- Advanced Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

PHERGain
PHERGain: 3-Yr iDFS Results From the Phase II Trial of Chemotherapy De‑escalation in HER2+ Early Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2023

PALMIRA
Phase II PALMIRA: Second-line ET ± Palbociclib Maintenance in Patients With HR+/HER2- Advanced Breast Cancer After Clinical Benefit on First-line Palbociclib + ET
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

TROPiCS-02 Final Analysis
TROPiCS-02: Final OS Analysis of the Phase III Trial of Sacituzumab Govitecan vs Treatment of Physician’s Choice in HR+/HER2- Advanced Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2023

PADA-1 Update
Phase III PADA-1 Update: Palbociclib + Switching to Fulvestrant vs Continuing AI Therapy in ER+/HER2- MBC With Rising ESR1 Mutations by ctDNA Analysis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2023

HER3-DXd in HER2- Breast Cancer
Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HER2-Negative Metastatic Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2023

NATALEE
NATALEE: Phase III Trial of Adjuvant Ribociclib + Nonsteroidal Aromatase Inhibitor vs Nonsteroidal Aromatase Inhibitor Alone for HR+/HER2- EBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2023

SOFT: Prognostic/Predictive Analyses
Evaluation of the Prognostic and Predictive Value of PAM50 Intrinsic Subtypes and ROR Scores in Premenopausal Women With HR+/HER2- Early Breast Cancer Enrolled in the SOFT Trial
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2023

T-DXd Efficacy/Safety: Age Analysis
Pooled Analysis of Trastuzumab Deruxtecan Efficacy and Safety by Age in Patients With HER2+ Metastatic Breast Cancer From DESTINY-Breast01, 02, and 03 Trials
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2023

Faculty

cover img faculity

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Chair, Breast Executive Committee
Sarah Cannon Research Institute
Nashville, Tennessee

cover img faculity

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Gilead, and Merck Sharp & Dohme Corp.

AstraZeneca

Daiichi Sankyo

Gilead

Merck Sharp & Dohme Corp.